Tablet-Based Neurocognitive Tests for Ugandan Adolescents Living With HIV: Cross-Sectional Validation Study
JMIR mHealth and uHealth · 2026-10-13 · 14 · e103288-e103288
DOI: 10.2196/103288 ↗Astratt
Abstract Background Adolescents living with perinatally acquired HIV (PHIV) remain at risk of neurocognitive difficulties, yet access to valid neurocognitive tests is limited in sub-Saharan Africa (SSA), where most of this population resides. Tests that can be administered by nonspecialist personnel are culturally and linguistically appropriate for SSA’s diverse populations and are brief enough for routine use are needed to expand access, but few such tools exist. Objective We adapted NeuroScreen , a brief tablet-based neurocognitive test battery, into Luganda and evaluated its validity and acceptability for use among Ugandan adolescents with PHIV. Methods In this cross-sectional validation study, 100 Ugandan adolescents aged 11 to 20 years (50 with PHIV; 50 HIV-negative controls) completed the Luganda- or English-language NeuroScreen battery and a commonly used traditional test battery. Participants were recruited from an existing longitudinal cardiovascular cohort at the Joint Clinical Research Centre in Kampala, Uganda. We examined convergent validity with correlations between the 2 batteries’ individual and global z -scores, known-groups validity with unadjusted and age-adjusted group comparisons, criterion validity by examining classification agreement between the 2 batteries quantified with Cohen κ, and acceptability through self-reported technology use and ease of use. Results NeuroScreen and the traditional battery global z -scores were strongly correlated ( r =0.75; P
EUVIMED